Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.57 USD | -2.46% | -5.05% | -59.39% |
Financials (USD)
Sales 2024 * | 282M | Sales 2025 * | 386M | Capitalization | 372M |
---|---|---|---|---|---|
Net income 2024 * | -185M | Net income 2025 * | -89M | EV / Sales 2024 * | 2.42 x |
Net Debt 2024 * | 309M | Net Debt 2025 * | 230M | EV / Sales 2025 * | 1.56 x |
P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-3.38
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.53% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -2.46% | ||
1 week | -5.05% | ||
Current month | -27.44% | ||
1 month | -26.69% | ||
3 months | -37.48% | ||
6 months | -58.73% | ||
Current year | -59.39% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 3.57 | -2.46% | 1,789,023 |
24-04-23 | 3.66 | +0.55% | 1,588,720 |
24-04-22 | 3.64 | -3.70% | 1,812,785 |
24-04-19 | 3.78 | -0.26% | 1,647,559 |
24-04-18 | 3.79 | +0.80% | 1,598,010 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.39% | 372M | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+53.11% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
-0.22% | 8.31B |
- Stock Market
- Equities
- RVNC Stock